N
Naoto T. Ueno
Researcher at University of Texas MD Anderson Cancer Center
Publications - 390
Citations - 13778
Naoto T. Ueno is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Breast cancer & Inflammatory breast cancer. The author has an hindex of 59, co-authored 389 publications receiving 11623 citations. Previous affiliations of Naoto T. Ueno include University of Texas Health Science Center at Houston & The Breast Cancer Research Foundation.
Papers
More filters
Journal ArticleDOI
In response to “outcomes of patients with inflammatory breast cancer treated by breast conserving surgery”: the argument against breast conservation and sentinel lymph node biopsy in IBC
TL;DR: Thirty-five patients who were diagnosed with IBC from 1999 to 2013 and treated with BCT were reviewed from a prospectively collected database, and BCT and SLND remain controversial in the treatment of IBC.
Journal ArticleDOI
Validation of an immunomodulatory gene signature algorithm to predict response to neoadjuvant immunochemotherapy in patients with primary triple-negative breast cancer.
Toshiaki Iwase,Lajos Pusztai,Kim Blenman,Xiaotong Li,Robert S. Seitz,Tyler J. Nielsen,Brock L. Schweitzer,David R. Hout,Daniel B. Bailey,Xiang Zhang,Yichao Shen,Naoto T. Ueno +11 more
TL;DR: A 101-gene algorithm established as a molecular subtyping method for triple-negative breast cancer (TNBC) includes assignment of an immunomodulatory (IM) subtype based on genes actively regulated by the immune system.
Posted ContentDOI
NDRG1 expression is an independent prognostic factor in inflammatory breast cancer
Emilly S. Villodre,Yun Gong,Lei Huo,Esther C. Yoon,Naoto T. Ueno,Wendy A. Woodward,Debu Tripathy,Juhee Song,Bisrat G. Debeb +8 more
TL;DR: NDRG1 correlated positively with aggressive tumor characteristics in IBC and was a significant independent prognostic factor for DSS and OSS in I BC patients and may represent a novel strategy for improving clinical outcomes for patients with IBC.
Journal ArticleDOI
Breast cancer evaluation and targeted investigational therapy (BEAT-IT): A pilot prospective tissue testing to guide clinical trial selection.
Lajos Pusztai,D. Mattair,Naoto T. Ueno,Vicente Valero,Stacy L. Moulder,James L. Murray,Ricardo H. Alvarez,Mariana Chavez-Mac Gregor,Lumarie Santiago,Rony Avritscher,Aysegul A. Sahin,Gabriel N. Hortobagyi,William Fraser Symmans,Funda Meric-Bernstam,Elizabeth M. Burton,Ana M. Gonzalez-Angulo +15 more
TL;DR: The hypothesis is that cancers that carry a molecular abnormality that corresponds to the mechanism of action of a given investigational drug are more sensitive to that particular drug than other cancers.